COMPANY
PRESENTATION

WARSAW // 2023

COMPANY PRESENTATION

Evolution from branded generics to innovations

Timeline

COMPANY PRESENTATION

Company highlights

Founded in

Unique hybrid model combining positive cash flows and integrated pharma business experience with a diversified pipeline of highly innovative programs Disciplined new program selection, focusing on un-met medical needs.

Driven by the best people

+

employees Highly experienced management team Founder-led teams with scientific backgrounds:

+

scientists.

Broad pipeline of

clinical stage assets and multiple identified leads targeting large market opportunities in neuropsychiatry, oncology, metabolism & inflammation Potential blockbusters with wholly owned IP Advanced early-stage pipeline:

innovative programs in pre-clinical.

Footprint in

>

countries Diversified enabling internal resources portfolio leading to the improved probability of success Collaborating at center of the biotech ecosystem.

COMPANY PRESENTATION

Led by a seasoned management team

Maciej Wieczorek, PhD

CEO, President of the Management Board

Founder and President of the Management Board of Celon Pharma PhD in Medical Biology at the Medical University of Lodz (PL) Scholarship of New University of Lisbon in Portugal, while also completed MBA at the Warsaw School of Economics and the University of Minnesota Inventor or co-inventor of several patent applications for classic chemical and biotechnological drugs, as well as the driving force for the launch of several of the best-selling drugs in Poland

Dorota Zwolińska

CFO

Manager with 15 years of experience in broadly understood financial analysis and controlling. She gained her experience at EY (formerly Ernst & Young), where in 2006-2013 she participated in numerous financial due diligence processes for the needs of mergers and acquisitions. In the years 2013-2016 as the Deputy Director at PKP CARGO S.A. she was responsible for building the operational and financial controlling functions. She was a member of the Supervisory Board of PKP Cargotabor sp.z o.o. in the years 2014-2016. In the years 2016-2021 she was employed at RADPOL SA, as the Financial Director.

COMPANY PRESENTATION

Segment dynamics - FY 2021/2022

 

Well balanced business model.

 

BRANDED
GENERICS

BRANDED GENERICS

Key strategic competences

Various pharmaceutical forms development

Intellectual property
management

GMP Manufacturing - dry forms and dry powder inhalers

Global regulatory
& supply chain

Full size commercial infrastructure in Poland and global network of partnerships outside Poland

Various pharmaceutical forms development

Intellectual property management

GMP Manufacturing - dry forms and dry powder inhalers

Global regulatory & supply chain

Full size commercial infrastructure in Poland and global network of partnerships outside Poland

BRANDED GENERICS

sales 2022

BRANDED GENERICS

Improved sales dynamics in Poland in 2022


Sell-out data are sourced from the pharmacy market and include margins of the distributors. Sell-out data do not constitute a basis for recognition of the Company's revenues and should not be considered as statutory accounting data reported by the Company.

BRANDED GENERICS

incubation of technologies and capabilities and strong and growing source of cash flows

2020

. mln USD

2021

. mln USD*

*without profit sharing

2022

. mln USD

INNOVATIVE
BUSINESS

INNOVATIVE BUSINESS

Therapeutic areas

INNOVATIVE BUSINESS

New R&D centre: total capacity increased by ~3x

200+

scientists

More than

46.000 m²

NEW
• Recombinant biotech: mammalian & microbiomes Modern analytics
• Modern analytics
• mRNA platform: core competencies in mRNA technology in one place

INNOVATIVE BUSINESS

Diversified platforms drives strong pipeline

INNOVATIVE BUSINESS

News flow & key milestones 2023/2024

INNOVATIVE BUSINESS

Partnering strategy 2023/2024

INNOVATIVE BUSINESS

Strategic focus

During the last 5 years, Celon has delivered 6 successful data readouts, initiated 11 clinical trials, and raised capital through EU-found financings and public offerings.

Celon is led by a strong management team that brings to the organization a combined track record of managing national and global companies.

We aim to be resource- and capital-efficient in the development of our therapeutic candidates by selectively accessing complementary expertise and infrastructure through strategic partnerships.

We are building a leading innovative R&D and Clinical Development team that we believe has a unique perspective about how to identify high-potential product candidates and unlock their full value.

We are actively seeking opportunities to partner in terms of our clinical and preclinical programs by acquisition, in-licensing, or co-development.

During the last 5 years, Celon has delivered 6 successful data readouts, initiated 11 clinical trials, and raised capital through EU-found financings and public offerings.

Celon is led by a strong management team that brings to the organization a combined track record of managing national and global companies.

We aim to be resource- and capital-efficient in the development of our therapeutic candidates by selectively accessing complementary expertise and infrastructure through strategic partnerships.

We are building a leading innovative R&D and Clinical Development team that we believe has a unique perspective about how to identify high-potential product candidates and unlock their full value.

We are actively seeking opportunities to partner in terms of our clinical and preclinical programs by acquisition, in-licensing, or co-development.

Contact

Contact Us

Celon Pharma S.A

Ogrodowa 2A,
05-092 Łomianki / Kiełpin

Call:

+48 22 751 59 33

Loading
Your message has been sent. Thank you!